This approach has shown early promise, as transgenic models of PDAC with either the genetic [149] or pharmacologic [148] inhibition of TGFBR1 display increased sensitivity to PD-1 inhibition, with similar results observed in both a subcutaneous xenograft model and orthotopic tumor models using pH-responsive clustered nanoparticles to inhibit both TGFβ and PD-L1 [151]. This evidence concerns the gene CD274 and neoplasm.